{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T23:18:29Z","timestamp":1778887109482,"version":"3.51.4"},"publisher-location":"Cham","reference-count":113,"publisher":"Springer Nature Switzerland","isbn-type":[{"value":"9783031972416","type":"print"},{"value":"9783031972423","type":"electronic"}],"license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1007\/978-3-031-97242-3_11","type":"book-chapter","created":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T20:23:35Z","timestamp":1755894215000},"page":"221-266","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pancreatic Cancer Immunotherapy: A Team-Based Approach"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-4431-5972","authenticated-orcid":false,"given":"Krushangi","family":"Patel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Percy","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julius","family":"Weng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laleh","family":"Melstrom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mustafa","family":"Raoof","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,23]]},"reference":[{"key":"11_CR1","unstructured":"American Cancer Society. Key statistics for pancreatic cancer [Internet]. www.cancer.org. 2024. Available from: https:\/\/www.cancer.org\/cancer\/types\/pancreatic-cancer\/about\/key-statistics.html"},{"key":"11_CR2","unstructured":"National Cancer Institute. Cancer of the pancreas\u2014cancer stat facts [Internet]. SEER. National Cancer Institute; 2018. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/pancreas.html"},{"issue":"1","key":"11_CR3","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13045-024-01561-6","volume":"17","author":"P Farhangnia","year":"2024","unstructured":"Farhangnia P, Khorramdelazad H, Nickho H, Delbandi AA. Current and future immunotherapeutic approaches in pancreatic cancer treatment. J Hematol Oncol. 2024;17(1):40.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"11_CR4","doi-asserted-by":"publisher","first-page":"15095","DOI":"10.1038\/ncomms15095","volume":"8","author":"JL Carstens","year":"2017","unstructured":"Carstens JL, Correa de Sampaio P, Yang D, Barua S, Wang H, Rao A, et al. Spatial computation of intratumoral T cells correlates with survival of patients with pancreatic cancer. Nat Commun. 2017;8(1):15095.","journal-title":"Nat Commun"},{"key":"11_CR5","doi-asserted-by":"crossref","unstructured":"Orhan A, Vogelsang RP, Andersen MB, Madsen MT, H\u00f6lmich ER, Raskov H, et al. The prognostic value of tumour-infiltrating lymphocytes in pancreatic cancer: a systematic review and meta-analysis. Eur J Cancer [Internet]. 2020 [cited 2023 Jan 2];132(0959\u20138049):71\u201384. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0959804920301544","DOI":"10.1016\/j.ejca.2020.03.013"},{"key":"11_CR6","doi-asserted-by":"crossref","unstructured":"Alam MS, Gaida MM, Bergmann F, Lasitschka F, Giese T, Giese NA, et al. Selective inhibition of the p38 alternative activation pathway in infiltrating T cells inhibits pancreatic cancer progression. Nat Med [Internet]. 2015 [cited 2025 Apr 6];21(11):1337\u201343. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC4636461\/","DOI":"10.1038\/nm.3957"},{"issue":"6","key":"11_CR7","doi-asserted-by":"publisher","first-page":"e2020395118","DOI":"10.1073\/pnas.2020395118","volume":"118","author":"G Mucciolo","year":"2021","unstructured":"Mucciolo G, Curcio C, Roux C, Li WY, Capello M, Curto R, et al. IL17A critically shapes the transcriptional program of fibroblasts in pancreatic cancer and switches on their protumorigenic functions. Proc Natl Acad Sci. 2021;118(6):e2020395118.","journal-title":"Proc Natl Acad Sci"},{"issue":"8","key":"11_CR8","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1136\/gutjnl-2022-327855","volume":"72","author":"F Simon","year":"2023","unstructured":"Simon F, Lutz V, Brichkina A, Neuhaus F, Ruckenbrod T, Hupfer A, et al. IL-17A-producing CD8+T cells promote PDAC via induction of inflammatory cancer-associated fibroblasts. Gut. 2023;72(8):1510\u201322.","journal-title":"Gut"},{"key":"11_CR9","doi-asserted-by":"crossref","unstructured":"Castro-Pando S, Howell RM, Li L, Mascaro M, Faraoni EY, Roux OL, et al. Pancreatic epithelial IL17\/IL17RA signaling drives B7-H4 expression to promote tumorigenesis. Cancer Immunol Res [Internet]. 2024 [cited 2025 Apr 7];12(9):1170\u201383. Available from: https:\/\/aacrjournals.org\/cancerimmunolres\/article\/12\/9\/1170\/747082\/Pancreatic-Epithelial-IL17-IL17RA-Signaling-Drives","DOI":"10.1158\/2326-6066.CIR-23-0527"},{"key":"11_CR10","doi-asserted-by":"crossref","unstructured":"Saravia J, Chapman NM, Chi H. Helper T cell differentiation. Cell Mol Immunol [Internet]. 2019 [cited 2020 Aug 20];16(7):634\u201343. Available from: https:\/\/www.nature.com\/articles\/s41423-019-0220-6","DOI":"10.1038\/s41423-019-0220-6"},{"issue":"5","key":"11_CR11","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1053\/j.gastro.2013.07.025","volume":"145","author":"A Ene-Obong","year":"2013","unstructured":"Ene-Obong A, Clear AJ, Watt J, Wang J, Fatah R, Riches JC, et al. Activated pancreatic stellate cells sequester CD8+ T cells to reduce their infiltration of the juxtatumoral compartment of pancreatic ductal adenocarcinoma. Gastroenterology. 2013;145(5):1121\u201332.","journal-title":"Gastroenterology"},{"issue":"7681","key":"11_CR12","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/nature24462","volume":"551","author":"VP Balachandran","year":"2017","unstructured":"Balachandran VP, \u0141uksza M, Zhao JN, Makarov V, Moral JA, Remark R, et al. Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature. 2017;551(7681):512\u20136.","journal-title":"Nature"},{"issue":"12","key":"11_CR13","doi-asserted-by":"publisher","first-page":"3129","DOI":"10.1158\/1078-0432.CCR-16-2128","volume":"23","author":"D Balli","year":"2017","unstructured":"Balli D, Rech AJ, Stanger BZ, Vonderheide RH. Immune cytolytic activity stratifies molecular subsets of human pancreatic cancer. Clin Cancer Res. 2017;23(12):3129\u201338.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"11_CR14","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.ccr.2014.04.020","volume":"25","author":"H Vonderheide Robert","year":"2014","unstructured":"Vonderheide Robert H. Tumor-promoting inflammatory networks in pancreatic neoplasia: another reason to loathe Kras. Cancer Cell. 2014;25(5):553\u20134.","journal-title":"Cancer Cell"},{"issue":"6","key":"11_CR15","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/j.ccr.2012.04.024","volume":"21","author":"Y Pylayeva-Gupta","year":"2012","unstructured":"Pylayeva-Gupta Y, Lee K, Hajdu Cristina H, Miller G, Bar-Sagi D. Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia. Cancer Cell. 2012;21(6):836\u201347.","journal-title":"Cancer Cell"},{"issue":"7","key":"11_CR16","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/nri2343","volume":"8","author":"DAA Vignali","year":"2008","unstructured":"Vignali DAA, Collison LW, Workman CJ. How regulatory T cells work. Nat Rev Immunol [Internet]. 2008;8(7):523\u201332. Available from: https:\/\/www.nature.com\/articles\/nri2343","journal-title":"Nat Rev Immunol [Internet]"},{"key":"11_CR17","doi-asserted-by":"crossref","unstructured":"Hiraoka N, Onozato K, Kosuge T, Hirohashi S. Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res [Internet]. 2006 [cited 2019 Dec 11];12(18):5423\u201334. Available from: https:\/\/clincancerres.aacrjournals.org\/content\/12\/18\/5423?ijkey=1f82553a4f1cf3c621cb809eadb7c83921b342b5&keytype2=tf_ipsecsha","DOI":"10.1158\/1078-0432.CCR-06-0369"},{"issue":"10","key":"11_CR18","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41568-022-00491-0","volume":"22","author":"TJ Laskowski","year":"2022","unstructured":"Laskowski TJ, Biederst\u00e4dt A, Rezvani K. Natural killer cells in antitumour adoptive cell immunotherapy. Nat Rev Cancer. 2022;22(10):557\u201375.","journal-title":"Nat Rev Cancer"},{"key":"11_CR19","doi-asserted-by":"crossref","unstructured":"Guerra N, Tan YX, Joncker NT, Choy A, Gallardo F, Xiong N, et al. NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity [Internet]. 2008 [cited 2019 Dec 12];28(4):571\u201380. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3528789\/","DOI":"10.1016\/j.immuni.2008.02.016"},{"issue":"2","key":"11_CR20","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ccell.2017.06.009","volume":"32","author":"A L\u00f3pez-Soto","year":"2017","unstructured":"L\u00f3pez-Soto A, Gonzalez S, Smyth MJ, Galluzzi L. Control of metastasis by NK cells. Cancer Cell. 2017;32(2):135\u201354.","journal-title":"Cancer Cell"},{"issue":"1","key":"11_CR21","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/s41423-018-0014-2","volume":"16","author":"Q Huang","year":"2018","unstructured":"Huang Q, Huang M, Meng F, Sun R. Activated pancreatic stellate cells inhibit NK cell function in the human pancreatic cancer microenvironment. Cell Mol Immunol. 2018;16(1):87\u20139.","journal-title":"Cell Mol Immunol"},{"key":"11_CR22","doi-asserted-by":"crossref","unstructured":"Walle T, Kraske JA, Liao B, Lenoir B, Timke C, von Bohlen Und Halbach E, et al. Radiotherapy orchestrates natural killer cell dependent antitumor immune responses through CXCL8. Sci Adv [Internet]. 2022 [cited 2023 Mar 14];8(12):eabh4050. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/35319989\/","DOI":"10.1126\/sciadv.abh4050"},{"issue":"3","key":"11_CR23","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.ccell.2020.02.008","volume":"37","author":"S Hegde","year":"2020","unstructured":"Hegde S, Krisnawan VE, Herzog BH, Zuo C, Breden MA, Knolhoff BL, et al. Dendritic cell paucity leads to dysfunctional immune surveillance in pancreatic cancer. Cancer Cell. 2020;37(3):289\u2013307.e9.","journal-title":"Cancer Cell"},{"key":"11_CR24","doi-asserted-by":"crossref","unstructured":"Takahashi K, Hideyoshi Toyokawa, Takai S, Sohei Satoi, Hiroaki Yanagimoto, Naoyoshi Terakawa, et al. Surgical influence of pancreatectomy on the function and count of circulating dendritic cells in patients with pancreatic cancer. Cancer Immunol Immunother [Internet]. 2005 [cited 2025 Apr 7];55(7):775\u201384. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC11029902\/","DOI":"10.1007\/s00262-005-0079-5"},{"issue":"5","key":"11_CR25","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.3390\/cancers14051216","volume":"14","author":"I Plesca","year":"2022","unstructured":"Plesca I, Bene\u0161ov\u00e1 I, Beer C, Sommer U, M\u00fcller L, Wehner R, et al. Clinical significance of tumor-infiltrating conventional and plasmacytoid dendritic cells in pancreatic ductal adenocarcinoma. Cancers [Internet]. 2022;14(5):1216. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC8909898\/","journal-title":"Cancers [Internet]"},{"issue":"3","key":"11_CR26","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1084\/jem.20031435","volume":"200","author":"A Thomas","year":"2004","unstructured":"Thomas A, Santarsiero LM, Lutz ER, Armstrong TD, Chen YC, Huang L, et al. Mesothelin-specific CD8+ T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. J Exp Med. 2004;200(3):297\u2013306.","journal-title":"J Exp Med"},{"issue":"12","key":"11_CR27","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1038\/nri1733","volume":"5","author":"S Gordon","year":"2005","unstructured":"Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol. 2005;5(12):953\u201364.","journal-title":"Nat Rev Immunol"},{"issue":"7","key":"11_CR28","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","volume":"14","author":"A Mantovani","year":"2017","unstructured":"Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P. Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol. 2017;14(7):399\u2013416.","journal-title":"Nat Rev Clin Oncol"},{"key":"11_CR29","doi-asserted-by":"crossref","unstructured":"Zeng W, Li F, Jin S, Ho PC, Liu PS, Xie X. Functional polarization of tumor-associated macrophages dictated by metabolic reprogramming. J Exp Clin Cancer Res [Internet]. 2023;42(1). Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC10517486\/","DOI":"10.1186\/s13046-023-02832-9"},{"issue":"26","key":"11_CR30","doi-asserted-by":"publisher","first-page":"5158","DOI":"10.1038\/s41388-019-0782-x","volume":"38","author":"JE Park","year":"2019","unstructured":"Park JE, Dutta B, Tse SW, Gupta N, Tan CF, Low JK, et al. Hypoxia-induced tumor exosomes promote M2-like macrophage polarization of infiltrating myeloid cells and microRNA-mediated metabolic shift. Oncogene. 2019;38(26):5158\u201373.","journal-title":"Oncogene"},{"key":"11_CR31","doi-asserted-by":"crossref","unstructured":"Sanford DE, Belt BA, Panni RZ, Mayer A, Deshpande AD, Carpenter D, et al. Inflammatory monocyte mobilization decreases patient survival in pancreatic cancer: a role for targeting the CCL2\/CCR2 axis. Clin Cancer Res [Internet]. 2013 [cited 2021 Feb 23];19(13):3404\u201315. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3700620\/","DOI":"10.1158\/1078-0432.CCR-13-0525"},{"key":"11_CR32","doi-asserted-by":"crossref","unstructured":"Yang S, Liu Q, Liao Q. Tumor-associated macrophages in pancreatic ductal adenocarcinoma: origin, polarization, function, and reprogramming. Front Cell Dev Biol [Internet]. 2021 [cited 2022 Jan 16];8:607209. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC7829544\/","DOI":"10.3389\/fcell.2020.607209"},{"issue":"8","key":"11_CR33","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41577-020-00490-y","volume":"21","author":"F Veglia","year":"2021","unstructured":"Veglia F, Sanseviero E, Gabrilovich DI. Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. Nat Rev Immunol. 2021;21(8):485\u201398.","journal-title":"Nat Rev Immunol"},{"issue":"9","key":"11_CR34","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1007\/s00262-011-1178-0","volume":"61","author":"MR Porembka","year":"2012","unstructured":"Porembka MR, Mitchem JB, Belt BA, Hsieh CS, Lee HM, Herndon J, et al. Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth. Cancer Immunol Immunother. 2012;61(9):1373\u201385.","journal-title":"Cancer Immunol Immunother"},{"issue":"324","key":"11_CR35","doi-asserted-by":"publisher","first-page":"ra42","DOI":"10.1126\/scisignal.2005049","volume":"7","author":"W Zhang","year":"2014","unstructured":"Zhang W, Nandakumar N, Shi Y, Manzano M, Smith A, Graham G, et al. Downstream of mutant KRAS, the transcription regulator YAP is essential for neoplastic progression to pancreatic ductal adenocarcinoma. Sci Signal. 2014;7(324):ra42.","journal-title":"Sci Signal"},{"key":"11_CR36","doi-asserted-by":"crossref","unstructured":"Hagenbeek TJ, Zbieg JR, Hafner M, Mroue R, Lacap JA, Sodir NM, et al. An allosteric pan-TEAD inhibitor blocks oncogenic YAP\/TAZ signaling and overcomes KRAS G12C inhibitor resistance. Nat Cancer [Internet]. 2023 [cited 2023 Oct 25];4(6):812\u201328. Available from: https:\/\/www.nature.com\/articles\/s43018-023-00577-0","DOI":"10.1038\/s43018-023-00577-0"},{"issue":"7","key":"11_CR37","first-page":"1102","volume":"5","author":"EA Chapeau","year":"2024","unstructured":"Chapeau EA, Sansregret L, Galli GG, Ch\u00e8ne P, Wartmann M, Mourikis TP, et al. Direct and selective pharmacological disruption of the YAP\u2013TEAD interface by IAG933 inhibits Hippo-dependent and RAS\u2013MAPK-altered cancers. Nat Can. 2024;5(7):1102\u201320.","journal-title":"Nat Can"},{"issue":"2","key":"11_CR38","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41571-023-00846-y","volume":"21","author":"SA Lasser","year":"2024","unstructured":"Lasser SA, Ozbay Kurt FG, Arkhypov I, Utikal J, Umansky V. Myeloid-derived suppressor cells in cancer and cancer therapy. Nat Rev Clin Oncol [Internet]. 2024;21(2):147\u201364. Available from: https:\/\/www.nature.com\/articles\/s41571-023-00846-y#:~:text=MDSCs%20support%20the%20progression%20of%20most%20cancer%20entities","journal-title":"Nat Rev Clin Oncol [Internet]"},{"key":"11_CR39","doi-asserted-by":"crossref","unstructured":"Ng M, Kwok I, Tan L, Shi C, Cerezo-Wallis D, Tan Y, et al. Deterministic reprogramming of neutrophils within tumors. Science. 2024;383(6679)","DOI":"10.1126\/science.adf6493"},{"issue":"4","key":"11_CR40","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41577-019-0141-8","volume":"19","author":"LG Ng","year":"2019","unstructured":"Ng LG, Ostuni R, Hidalgo A. Heterogeneity of neutrophils. Nat Rev Immunol. 2019;19(4):255\u201365.","journal-title":"Nat Rev Immunol"},{"issue":"8","key":"11_CR41","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1038\/nm.3909","volume":"21","author":"AJ Gentles","year":"2015","unstructured":"Gentles AJ, Newman AM, Liu CL, Bratman SV, Feng W, Kim D, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med. 2015;21(8):938\u201345.","journal-title":"Nat Med"},{"issue":"11","key":"11_CR42","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1158\/2326-6066.CIR-16-0188","volume":"4","author":"T Chao","year":"2016","unstructured":"Chao T, Furth EE, Vonderheide RH. CXCR2-dependent accumulation of tumor-associated neutrophils regulates T-cell immunity in pancreatic ductal adenocarcinoma. Cancer Immunol Res. 2016;4(11):968\u201382.","journal-title":"Cancer Immunol Res"},{"key":"11_CR43","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.3389\/fonc.2019.01146","volume":"9","author":"MT Masucci","year":"2019","unstructured":"Masucci MT, Minopoli M, Carriero MV. Tumor associated neutrophils. Their role in tumorigenesis, metastasis, prognosis and therapy. Front Oncol. 2019;9:1146.","journal-title":"Front Oncol"},{"key":"11_CR44","doi-asserted-by":"crossref","unstructured":"Nielsen SR, Str\u00f8bech JE, Horton ER, Jackstadt R, Laitala A, Bravo MC, et al. Suppression of tumor-associated neutrophils by lorlatinib attenuates pancreatic cancer growth and improves treatment with immune checkpoint blockade. Nat Commun [Internet]. 2021;12(1):3414. Available from: https:\/\/www.nature.com\/articles\/s41467-021-23731-7","DOI":"10.1038\/s41467-021-23731-7"},{"issue":"1","key":"11_CR45","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13046-023-02935-3","volume":"43","author":"W Luo","year":"2024","unstructured":"Luo W, Wen T, Qu X. Tumor immune microenvironment-based therapies in pancreatic ductal adenocarcinoma: time to update the concept. J Exp Clin Cancer Res. 2024;43(1):8.","journal-title":"J Exp Clin Cancer Res"},{"issue":"2","key":"11_CR46","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1136\/gutjnl-2019-319912","volume":"70","author":"R Takahashi","year":"2021","unstructured":"Takahashi R, Macchini M, Sunagawa M, Jiang Z, Tanaka T, Valenti G, et al. Interleukin-1\u03b2-induced pancreatitis promotes pancreatic ductal adenocarcinoma via B lymphocyte-mediated immune suppression. Gut [Internet]. 2021;70(2):330\u201341. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/32393543\/","journal-title":"Gut [Internet]"},{"issue":"3","key":"11_CR47","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1084\/jem.20181216","volume":"216","author":"AE Denton","year":"2019","unstructured":"Denton AE, Innocentin S, Carr EJ, Bradford BM, Lafouresse F, Mabbott NA, et al. Type I interferon induces CXCL13 to support ectopic germinal center formation. J Exp Med. 2019;216(3):621\u201337.","journal-title":"J Exp Med"},{"issue":"9","key":"11_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100744","volume":"3","author":"B Mirlekar","year":"2022","unstructured":"Mirlekar B, Wang Y, Li S, Zhou M, Entwistle S, De Buysscher T, et al. Balance between immunoregulatory B cells and plasma cells drives pancreatic tumor immunity. Cell Rep Med. 2022;3(9):100744.","journal-title":"Cell Rep Med"},{"issue":"3","key":"11_CR49","first-page":"292","volume":"8","author":"B Mirlekar","year":"2020","unstructured":"Mirlekar B, Michaud D, Lee SS, Kren NP, Harris CD, Greene KG, et al. B cell\u2013derived IL35 drives STAT3-dependent CD8+ T-cell exclusion in pancreatic. Cancer. 2020;8(3):292\u2013308.","journal-title":"Cancer"},{"issue":"7931","key":"11_CR50","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/s41586-022-05254-3","volume":"610","author":"S Li","year":"2022","unstructured":"Li S, Mirlekar B, Johnson BM, June Brickey W, Wrobel JA, Yang N, et al. STING-induced regulatory B cells compromise NK function in cancer immunity. Nature. 2022;610(7931):373\u201380.","journal-title":"Nature"},{"key":"11_CR51","doi-asserted-by":"crossref","unstructured":"Tempero M, Oh DY, Tabernero J, Reni M, Van Cutsem E, Hendifar A, et al. Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study. Ann Oncol [Internet]. 2021 [cited 2022 May 23];32(5):600\u20138. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/33539945\/","DOI":"10.1016\/j.annonc.2021.01.070"},{"key":"11_CR52","doi-asserted-by":"crossref","unstructured":"Bubin R, Romans Uljanovs, Ilze Strumfa. Cancer stem cells in pancreatic ductal adenocarcinoma. 2023 [cited 2023 Jun 8];24(8):7030\u20130. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC10138709\/","DOI":"10.3390\/ijms24087030"},{"issue":"1","key":"11_CR53","doi-asserted-by":"publisher","first-page":"3580","DOI":"10.1038\/s41467-024-47680-z","volume":"15","author":"CH Chang","year":"2024","unstructured":"Chang CH, Liu F, Militi S, Hester S, Nibhani R, Deng S, et al. The pRb\/RBL2-E2F1\/4-GCN5 axis regulates cancer stem cell formation and G0 phase entry\/exit by paracrine mechanisms. Nat Commun. 2024;15(1):3580.","journal-title":"Nat Commun"},{"key":"11_CR54","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.isci.2019.05.004","volume":"15","author":"M Ullah","year":"2019","unstructured":"Ullah M, Liu DD, Thakor AS. Mesenchymal stromal cell homing: mechanisms and strategies for improvement. iScience. 2019;15:421\u201338.","journal-title":"iScience"},{"issue":"5","key":"11_CR55","doi-asserted-by":"publisher","first-page":"785","DOI":"10.3892\/ol.2021.13046","volume":"22","author":"S Lim","year":"2021","unstructured":"Lim S, Khoo B. An overview of mesenchymal stem cells and their potential therapeutic benefits in cancer therapy (Review). Oncol Lett. 2021;22(5):785.","journal-title":"Oncol Lett"},{"issue":"8","key":"11_CR56","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1016\/j.cell.2023.03.016","volume":"186","author":"Y Chhabra","year":"2023","unstructured":"Chhabra Y, Weeraratna AT. Fibroblasts in cancer: unity in heterogeneity. Cell. 2023;186(8):1580\u2013609.","journal-title":"Cell"},{"issue":"8","key":"11_CR57","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1158\/2159-8290.CD-19-0094","volume":"9","author":"E Elyada","year":"2019","unstructured":"Elyada E, Bolisetty M, Laise P, Flynn WF, Courtois ET, Burkhart RA, et al. Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts. Cancer Discov. 2019;9(8):1102\u201323.","journal-title":"Cancer Discov"},{"issue":"6","key":"11_CR58","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.ccell.2022.04.011","volume":"40","author":"H Huang","year":"2022","unstructured":"Huang H, Wang Z, Zhang Y, Pradhan RN, Ganguly D, Chandra R, et al. Mesothelial cell-derived antigen-presenting cancer-associated fibroblasts induce expansion of regulatory T cells in pancreatic cancer. Cancer Cell. 2022;40(6):656\u2013673.e7.","journal-title":"Cancer Cell"},{"issue":"11","key":"11_CR59","doi-asserted-by":"publisher","first-page":"e146987","DOI":"10.1172\/JCI146987","volume":"131","author":"S Bhattacharjee","year":"2021","unstructured":"Bhattacharjee S, Hamberger F, Ravichandra A, Miller M, Nair A, Affo S, et al. Tumor restriction by type I collagen opposes tumor-promoting effects of cancer-associated fibroblasts. J Clin Invest. 2021;131(11):e146987.","journal-title":"J Clin Invest"},{"issue":"1","key":"11_CR60","doi-asserted-by":"publisher","first-page":"3593","DOI":"10.1038\/s41467-024-47949-3","volume":"15","author":"M Raymant","year":"2024","unstructured":"Raymant M, Astuti Y, Alvaro-Espinosa L, Green D, Quaranta V, Bellomo G, et al. Macrophage-fibroblast JAK\/STAT dependent crosstalk promotes liver metastatic outgrowth in pancreatic cancer. Nat Commun. 2024;15(1):3593.","journal-title":"Nat Commun"},{"issue":"3","key":"11_CR61","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1242\/jcs.03347","volume":"120","author":"W Schneiderhan","year":"2007","unstructured":"Schneiderhan W, Diaz F, Fundel M, Zhou S, Siech M, Hasel C, et al. Pancreatic stellate cells are an important source of MMP-2 in human pancreatic cancer and accelerate tumor progression in a murine xenograft model and CAM assay. J Cell Sci. 2007;120(3):512\u20139.","journal-title":"J Cell Sci"},{"issue":"21","key":"11_CR62","doi-asserted-by":"publisher","first-page":"4271","DOI":"10.1038\/s41388-020-1289-1","volume":"39","author":"DD Cave","year":"2020","unstructured":"Cave DD, Di Guida M, Costa V, Sevillano M, Ferrante L, Heeschen C, et al. TGF-\u03b21 secreted by pancreatic stellate cells promotes stemness and tumourigenicity in pancreatic cancer cells through L1CAM downregulation. Oncogene [Internet]. 2020;39(21):4271\u201385. Available from: https:\/\/www.nature.com\/articles\/s41388-020-1289-1","journal-title":"Oncogene [Internet]"},{"issue":"1","key":"11_CR63","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1146\/annurev-pathmechdis-031621-024600","volume":"18","author":"MH Sherman","year":"2023","unstructured":"Sherman MH, Beatty GL. Tumor microenvironment in pancreatic cancer pathogenesis and therapeutic resistance. Annu Rev Pathol Mech Dis. 2023;18(1):123\u201348.","journal-title":"Annu Rev Pathol Mech Dis"},{"key":"11_CR64","doi-asserted-by":"crossref","unstructured":"Rhim AD, Oberstein PE, Thomas DH, Mirek ET, Palermo CF, Sastra SA, et al. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell [Internet]. 2014 [cited 2021 Dec 9];25(6):735\u201347. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/24856585\/","DOI":"10.1016\/j.ccr.2014.04.021"},{"key":"11_CR65","doi-asserted-by":"publisher","first-page":"875188","DOI":"10.3389\/fonc.2022.875188","volume":"12","author":"M Nisar","year":"2022","unstructured":"Nisar M, Paracha RZ, Adil S, Qureshi SN, Janjua HA. An extensive review on preclinical and clinical trials of oncolytic viruses therapy for pancreatic cancer. Front Oncol. 2022;12:875188.","journal-title":"Front Oncol"},{"key":"11_CR66","doi-asserted-by":"crossref","unstructured":"Lou E. Oncolytic herpes viruses as a potential mechanism for cancer therapy. Acta Oncol (Stockholm, Sweden) [Internet]. 2003;42(7):660\u201371. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/14690152\/","DOI":"10.1080\/0284186031000518"},{"key":"11_CR67","doi-asserted-by":"crossref","unstructured":"Musher BL, Rowinsky EK, Smaglo BG, Abidi W, Othman M, Patel K, et al. LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): results from arm 1 of a non-randomised, single-centre, phase 1\/2 study. Lancet Oncol [Internet]. 2024 [cited 2025 Apr 8];25(4):488\u2013500. Available from: https:\/\/www.thelancet.com\/journals\/lanonc\/article\/PIIS1470-2045(24)00079-2\/abstract","DOI":"10.1016\/S1470-2045(24)00079-2"},{"key":"11_CR68","doi-asserted-by":"crossref","unstructured":"Mahalingam D, Chen S, Xie P, Loghmani H, Heineman T, Kalyan A, et al. Combination of pembrolizumab and pelareorep promotes anti-tumour immunity in advanced pancreatic adenocarcinoma (PDAC). Br J Cancer [Internet]. 2023 [cited 2025 Apr 8];129(5):782\u201390. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10449917\/","DOI":"10.1038\/s41416-023-02344-5"},{"issue":"12","key":"11_CR69","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1038\/s41587-023-02118-7","volume":"42","author":"Y Chen","year":"2024","unstructured":"Chen Y, Chen X, Bao W, Liu G, Wei W, Ping Y. An oncolytic virus\u2013T cell chimera for cancer immunotherapy. Nat Biotechnol. 2024;42(12):1876\u201387.","journal-title":"Nat Biotechnol"},{"issue":"4","key":"11_CR70","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/nrc2355","volume":"8","author":"SA Rosenberg","year":"2008","unstructured":"Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer [Internet]. 2008;8(4):299\u2013308. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC2553205\/","journal-title":"Nat Rev Cancer [Internet]"},{"issue":"4","key":"11_CR71","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nrc3245","volume":"12","author":"WH Fridman","year":"2012","unstructured":"Fridman WH, Pag\u00e8s F, Saut\u00e8s-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer [Internet]. 2012;12(4):298\u2013306. Available from: https:\/\/www.nature.com\/articles\/nrc3245","journal-title":"Nat Rev Cancer [Internet]"},{"issue":"1","key":"11_CR72","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s40425-016-0164-7","volume":"4","author":"M Hall","year":"2016","unstructured":"Hall M, Liu H, Malafa MP, Centeno BA, Hodul PJ, Pimiento JM, et al. Expansion of tumor-infiltrating lymphocytes (TIL) from human pancreatic tumors. J Immunother Cancer. 2016;4(1):61.","journal-title":"J Immunother Cancer"},{"key":"11_CR73","doi-asserted-by":"crossref","unstructured":"Levin N, Kim SP, Marquardt CA, Vale NR, Rosenberg SA. Neoantigen-specific stimulation of tumor-infiltrating lymphocytes enables effective TCR isolation and expansion while preserving stem-like memory phenotypes. J ImmunoTher Cancer [Internet]. 2024;12(5). Available from: https:\/\/www.researchgate.net\/publication\/381027736_Neoantigen-specific_stimulation_of_tumor-infiltrating_lymphocytes_enables_effective_TCR_isolation_and_expansion_while_preserving_stem-like_memory_phenotypes","DOI":"10.1136\/jitc-2023-008645"},{"key":"11_CR74","doi-asserted-by":"crossref","unstructured":"Henson SN, Elko EA, Swiderski PM, Liang Y, Engelbrektson AL, Pi\u00f1a A, et al. PepSeq: a fully in vitro platform for highly multiplexed serology using customizable DNA-barcoded peptide libraries. Nat Protocols [Internet]. 2022 [cited 2025 Apr 8];18(2):396\u2013423. Available from: https:\/\/www.nature.com\/articles\/s41596-022-00766-8","DOI":"10.1038\/s41596-022-00766-8"},{"key":"11_CR75","doi-asserted-by":"crossref","unstructured":"Chung V, Soldi R, Ghosh-Halder T, Huang P, Chih S, Lin M, et al. Clinical development of STL-101, a personalized Til therapy for treatment of advance solid tumors 1 [Internet]. [cited 2025 Apr 8]. Available from: https:\/\/jitc.bmj.com\/content\/jitc\/12\/Suppl_2\/A781.full.pdf","DOI":"10.1136\/jitc-2024-SITC2024.0681"},{"key":"11_CR76","doi-asserted-by":"crossref","unstructured":"Chung MJ, Park JY, Bang S, Park SW, Song SY. Phase II clinical trial of ex vivo-expanded cytokine-induced killer cells therapy in advanced pancreatic cancer. Cancer Immunol Immunother [Internet]. 2014 [cited 2025 Apr 8];63(9):939\u201346. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC11029701\/","DOI":"10.1007\/s00262-014-1566-3"},{"key":"11_CR77","doi-asserted-by":"crossref","unstructured":"Wang Z, Liu Y, Li R, Shang Y, Zhang Y, Zhao L, et al. Autologous cytokine-induced killer cell transfusion increases overall survival in advanced pancreatic cancer. J Hematol Oncol [Internet]. 2016 [cited 2021 Nov 19];9:6. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4740990\/","DOI":"10.1186\/s13045-016-0237-6"},{"key":"11_CR78","doi-asserted-by":"crossref","unstructured":"Heumann T, Judkins C, Li K, Lim SJ, Hoare J, Parkinson R, et al. A platform trial of neoadjuvant and adjuvant antitumor vaccination alone or in combination with PD-1 antagonist and CD137 agonist antibodies in patients with resectable pancreatic adenocarcinoma. Nat Commun [Internet]. 2023 [cited 2023 Jul 17];14(1):3650. Available from: https:\/\/www.nature.com\/articles\/s41467-023-39196-9","DOI":"10.1038\/s41467-023-39196-9"},{"issue":"3","key":"11_CR79","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1080\/21645515.2015.1093264","volume":"12","author":"KA McCormick","year":"2015","unstructured":"McCormick KA, Coveler AL, Rossi GR, Vahanian NN, Link CJ, Gabriela Chiorean E. Pancreatic cancer: update on immunotherapies and algenpantucel-L. Hum Vaccin Immunother. 2015;12(3):563\u201375.","journal-title":"Hum Vaccin Immunother"},{"issue":"3","key":"11_CR80","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s10238-011-0159-0","volume":"12","author":"Y Rong","year":"2012","unstructured":"Rong Y, Qin X, Jin D, Lou W, Wu L, Wang D, et al. A phase I pilot trial of MUC1-peptide-pulsed dendritic cells in the treatment of advanced pancreatic cancer. Clin Exp Med [Internet]. 2012;12(3):173\u201380. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/21932124\/","journal-title":"Clin Exp Med [Internet]"},{"key":"11_CR81","doi-asserted-by":"crossref","unstructured":"Kobayashi M, Shimodaira S, Nagai K, Ogasawara M, Takahashi H, Abe H, et al. Prognostic factors related to add-on dendritic cell vaccines on patients with inoperable pancreatic cancer receiving chemotherapy: a multicenter analysis. Cancer Immunol Immunother [Internet]. 2014 [cited 2025 Apr 8];63(8):797\u2013806. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC11028555\/","DOI":"10.1007\/s00262-014-1554-7"},{"issue":"2","key":"11_CR82","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1097\/MPA.0b013e31822398c6","volume":"41","author":"Y Kimura","year":"2012","unstructured":"Kimura Y, Tsukada J, Tomoda T, Takahashi H, Imai K, Shimamura K, et al. Clinical and immunologic evaluation of dendritic cell\u2013based immunotherapy in combination with gemcitabine and\/or S-1 in patients with advanced pancreatic carcinoma. Pancreas. 2012;41(2):195\u2013205.","journal-title":"Pancreas"},{"issue":"11","key":"11_CR83","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1038\/sj.bjc.6603437","volume":"95","author":"SL Bernhardt","year":"2006","unstructured":"Bernhardt SL, Gjertsen MK, Trachsel S, M\u00f8ller M, Eriksen JA, Meo M, et al. Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose escalating phase I\/II study. Br J Cancer. 2006;95(11):1474\u201382.","journal-title":"Br J Cancer"},{"key":"11_CR84","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1186\/1479-5876-11-291","volume":"11","author":"S Asahara","year":"2013","unstructured":"Asahara S, Takeda K, Yamao K, Maguchi H, Yamaue H. Phase I\/II clinical trial using HLA-A24-restricted peptide vaccine derived from KIF20A for patients with advanced pancreatic cancer. J Transl Med [Internet]. 2013;11:291. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/24237633\/","journal-title":"J Transl Med [Internet]"},{"key":"11_CR85","unstructured":"Pant S, Wainberg ZA, Weekes CD, Furqan M, Kasi PM, Devoe CE, et al. Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial. Nat Med [Internet]. 2024 [cited 2024 Feb 3]:1\u201312. Available from: https:\/\/www.nature.com\/articles\/s41591-023-02760-3"},{"issue":"5","key":"11_CR86","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1053\/j.gastro.2013.01.020","volume":"144","author":"P Cappello","year":"2013","unstructured":"Cappello P, Rolla S, Chiarle R, Principe M, Cavallo F, Perconti G, et al. Vaccination with ENO1 DNA prolongs survival of genetically engineered mice with pancreatic cancer. Gastroenterology. 2013;144(5):1098\u2013106.","journal-title":"Gastroenterology"},{"issue":"2","key":"11_CR87","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001071","volume":"8","author":"G Mandili","year":"2020","unstructured":"Mandili G, Curcio C, Bulfamante S, Follia L, Ferrero G, Mazza E, et al. In pancreatic cancer, chemotherapy increases antitumor responses to tumor-associated antigens and potentiates DNA vaccination. J ImmunoTher Cancer [Internet]. 2020;8(2):e001071. Available from: https:\/\/jitc.bmj.com\/content\/8\/2\/e001071","journal-title":"J ImmunoTher Cancer [Internet]"},{"key":"11_CR88","doi-asserted-by":"crossref","unstructured":"Gong YF, Zhou QB, Liao YD, Mai C, Chen TJ, Tang YQ, et al. Optimized construction of MUC1-VNTRn DNA vaccine and its anti-pancreatic cancer efficacy. Oncol Lett [Internet]. 2017 [cited 2025 Apr 8];13(4):2198\u2013206. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC5403551\/","DOI":"10.3892\/ol.2017.5717"},{"key":"11_CR89","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.omto.2022.07.008","volume":"26","author":"F Geng","year":"2022","unstructured":"Geng F, Dong L, Bao X, Guo Q, Guo J, Zhou Y, et al. CAFs\/tumor cells co-targeting DNA vaccine in combination with low-dose gemcitabine for the treatment of Panc02 murine pancreatic cancer. Mol Ther Oncolytics. 2022;26:304\u201313.","journal-title":"Mol Ther Oncolytics"},{"issue":"7963","key":"11_CR90","first-page":"1","volume":"618","author":"LA Rojas","year":"2023","unstructured":"Rojas LA, Sethna Z, Soares KC, Olcese C, Pang N, Patterson E, et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature [Internet]. 2023;618(7963):1\u20137. Available from: https:\/\/www.nature.com\/articles\/s41586-023-06063-y","journal-title":"Nature [Internet]"},{"issue":"12","key":"11_CR91","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1200\/JCO.2014.57.4244","volume":"33","author":"DT Le","year":"2015","unstructured":"Le DT, Wang-Gillam A, Picozzi V, Greten TF, Crocenzi T, Springett G, et al. Safety and survival with GVAX pancreas prime and listeria monocytogenes\u2013expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. J Clin Oncol [Internet]. 2015;33(12):1325\u201333. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4397277\/pdf\/zlj1325.pdf","journal-title":"J Clin Oncol [Internet]"},{"key":"11_CR92","doi-asserted-by":"publisher","first-page":"1228532","DOI":"10.3389\/fimmu.2023.1228532","volume":"14","author":"V Raman","year":"2023","unstructured":"Raman V, Howell LM, Shoshana HCL, Wetherby VE, Minter LM, et al. Intracellular Salmonella delivery of an exogenous immunization antigen refocuses CD8 T cells against cancer cells, eliminates pancreatic tumors and forms antitumor immunity. Front Immunol. 2023;14:1228532.","journal-title":"Front Immunol"},{"issue":"4","key":"11_CR93","first-page":"e1001217","volume":"4","author":"FH Schmitz-Winnenthal","year":"2015","unstructured":"Schmitz-Winnenthal FH, Hohmann N, Niethammer AG, Friedrich T, Lubenau H, Springer M, et al. Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic cancer: a randomized, placebo-controlled, phase 1 trial. Onco Targets Ther. 2015;4(4):e1001217.","journal-title":"Onco Targets Ther"},{"issue":"4","key":"11_CR94","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.stem.2018.01.016","volume":"22","author":"NG Kooreman","year":"2018","unstructured":"Kooreman NG, Kim Y, de Almeida PE, Termglinchan V, Diecke S, Shao NY, et al. Autologous iPSC-based vaccines elicit anti-tumor responses in vivo. Cell Stem Cell [Internet]. 2018;22(4):501\u2013513.e7. Available from: https:\/\/www.cell.com\/action\/showPdf?pii=S1934-5909%2818%2930016-X","journal-title":"Cell Stem Cell [Internet]"},{"key":"11_CR95","unstructured":"Ouyang X, Liu Y, Zhou Y, et al. Antitumor effects of iPSC-based cancer vaccine in pancreatic cancer. Stem Cell Rep [Internet]. 2021; Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2213671121001995?via%3Dihub"},{"key":"11_CR96","doi-asserted-by":"crossref","unstructured":"Lu H, Zheng LY, Wu LY, Chen J, Xu N, Mi SC. The immune escape signature predicts the prognosis and immunotherapy sensitivity for pancreatic ductal adenocarcinoma. Front Oncol [Internet]. 2022 [cited 2025 Apr 15];12. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9486201\/","DOI":"10.3389\/fonc.2022.978921"},{"issue":"1","key":"11_CR97","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s13059-021-02363-6","volume":"22","author":"WJ Ho","year":"2021","unstructured":"Ho WJ, Erbe R, Danilova L, Phyo Z, Bigelow E, Stein-O\u2019Brien G, et al. Multi-omic profiling of lung and liver tumor microenvironments of metastatic pancreatic cancer reveals site-specific immune regulatory pathways. Genome Biol. 2021;22(1):154.","journal-title":"Genome Biol"},{"issue":"4","key":"11_CR98","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.pan.2016.03.016","volume":"16","author":"S Kruger","year":"2016","unstructured":"Kruger S, Haas M, Burger PJ, Ormanns S, Modest DP, Westphalen CB, et al. Isolated pulmonary metastases define a favorable subgroup in metastatic pancreatic cancer. Pancreatology [Internet]. 2016;16(4):593\u20138. Available from: https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S1424390316300096?via%3Dihub","journal-title":"Pancreatology [Internet]"},{"key":"11_CR99","doi-asserted-by":"crossref","unstructured":"Tazdait M, Mezquita L, Lahmar J, Ferrara R, Bidault F, Ammari S, et al. Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: comparison of RECIST 1.1, irRECIST and iRECIST criteria. Eur J Cancer [Internet]. 2018 [cited 2020 Feb 26];88:38\u201347. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0959804917313576","DOI":"10.1016\/j.ejca.2017.10.017"},{"key":"11_CR100","doi-asserted-by":"publisher","first-page":"70","DOI":"10.3389\/fimmu.2018.00070","volume":"9","author":"AJ Oliver","year":"2018","unstructured":"Oliver AJ, Lau PKH, Unsworth AS, Loi S, Darcy PK, Kershaw MH, et al. Tissue-dependent tumor microenvironments and their impact on immunotherapy responses. Front Immunol. 2018;9:70.","journal-title":"Front Immunol"},{"issue":"4 Suppl","key":"11_CR101","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1200\/JCO.2025.43.4_suppl.688","volume":"43","author":"M Shahzad","year":"2025","unstructured":"Shahzad M, Vyas A, Dave P, Irfan S, Khan A, Chaudhry A, et al. Clinical outcomes of immunotherapy in metastatic pancreatic carcinoma: a systematic review and meta-analysis. J Clin Oncol. 2025;43(4 Suppl):688.","journal-title":"J Clin Oncol"},{"issue":"4 Suppl","key":"11_CR102","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1200\/JCO.2025.43.4_suppl.730","volume":"43","author":"T Seufferlein","year":"2025","unstructured":"Seufferlein T, Arnold D, Burkhart N, Reinacher-Schick AC, Ungerechts G, Martens UM, et al. GOBLET study: results of the safety run-in for first-line metastatic pancreatic ductal adenocarcinoma (PDAC) patients treated with pelareorep + modified FOLFIRINOX +\/\u2212 atezolizumab. J Clin Oncol. 2025;43(4 Suppl):730.","journal-title":"J Clin Oncol"},{"issue":"4 Suppl","key":"11_CR103","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1200\/JCO.2025.43.4_suppl.728","volume":"43","author":"AP Dean","year":"2025","unstructured":"Dean AP, Sjoquist K, Gebski V, Karapetis CS, Lomma C, Burge ME, et al. AGITG ASCEND: randomised, double-blind phase II study of certepetide or placebo added to gemcitabine plus nab-paclitaxel in patients with untreated metastatic pancreatic ductal adenocarcinoma: initial results. J Clin Oncol. 2025;43(4 Suppl):728.","journal-title":"J Clin Oncol"},{"issue":"4 Suppl","key":"11_CR104","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1200\/JCO.2025.43.4_suppl.746","volume":"43","author":"AP Dean","year":"2025","unstructured":"Dean AP, Johansson M, Yusoff I, Rao S, Sparrow S, Kumarasinghe P, et al. Immunotherapy engagement in pancreatic adenocarcinoma: provisional results of iLSTA study\u2014durvalumab, LSTA1 (certepetide), gemcitabine, and nab-paclitaxel for locally advanced pancreatic ductal adenocarcinoma. J Clin Oncol. 2025;43(4 Suppl):746.","journal-title":"J Clin Oncol"},{"issue":"4 Suppl","key":"11_CR105","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1200\/JCO.2025.43.4_suppl.754","volume":"43","author":"M Ebia","year":"2025","unstructured":"Ebia M, Abbas AA, Dotson S, Elmadbouh OHM, Davelaar J, Hendifar AE, et al. CD8+ T cell proximity analysis of the tumor microenvironment (TME) in patients with pancreatic ductal adenocarcinoma (PDAC) and associated clinical outcomes. J Clin Oncol. 2025;43(4 Suppl):754.","journal-title":"J Clin Oncol"},{"issue":"4","key":"11_CR106","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.cell.2019.07.008","volume":"178","author":"E Riquelme","year":"2019","unstructured":"Riquelme E, Zhang Y, Zhang L, Montiel M, Zoltan M, Dong W, et al. Tumor microbiome diversity and composition influence pancreatic cancer outcomes. Cell [Internet]. 2019;178(4):795\u2013806.e12. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC7288240\/pdf\/nihms-1537195.pdf","journal-title":"Cell [Internet]"},{"issue":"13","key":"11_CR107","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1002\/cncr.34748","volume":"129","author":"J Kharofa","year":"2023","unstructured":"Kharofa J, Haslam D, Wilkinson R, Weiss A, Patel S, Wang K, et al. Analysis of the fecal metagenome in long-term survivors of pancreas cancer. Cancer. 2023;129(13):1986\u201394.","journal-title":"Cancer"},{"issue":"1","key":"11_CR108","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s40164-023-00442-x","volume":"12","author":"M Zhang","year":"2023","unstructured":"Zhang M, Liu J, Xia Q. Role of gut microbiome in cancer immunotherapy: from predictive biomarker to therapeutic target. Exp Hematol Oncol. 2023;12(1):84.","journal-title":"Exp Hematol Oncol"},{"issue":"4 Suppl","key":"11_CR109","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1200\/JCO.2025.43.4_suppl.757","volume":"43","author":"AP Dean","year":"2025","unstructured":"Dean AP, Comito OR, Yusoff I, Rao S, Johansson M, Navadgi S, et al. Potential effect of the gut microbiome on tumour response to anti-cancer treatment in patients diagnosed with pancreatic ductal adenocarcinoma. J Clin Oncol. 2025;43(4 Suppl):757.","journal-title":"J Clin Oncol"},{"issue":"8","key":"11_CR110","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1038\/nrclinonc.2016.30","volume":"13","author":"MB Bernstein","year":"2016","unstructured":"Bernstein MB, Krishnan S, Hodge JW, Chang JY. Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach? Nat Rev Clin Oncol. 2016;13(8):516\u201324.","journal-title":"Nat Rev Clin Oncol"},{"issue":"7","key":"11_CR111","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1080\/09553002.2019.1623429","volume":"95","author":"EC Ko","year":"2019","unstructured":"Ko EC, Formenti SC. Radiation therapy to enhance tumor immunotherapy: a novel application for an established modality. Int J Radiat Biol. 2019;95(7):936\u20139.","journal-title":"Int J Radiat Biol"},{"key":"11_CR112","doi-asserted-by":"publisher","first-page":"110064","DOI":"10.1016\/j.radonc.2023.110064","volume":"191","author":"MD Chuong","year":"2024","unstructured":"Chuong MD, Lee P, Low DA, Kim J, Mittauer KE, Bassetti MF, et al. Stereotactic MR-guided on-table adaptive radiation therapy (SMART) for borderline resectable and locally advanced pancreatic cancer: a multi-center, open-label phase 2 study. Radiother Oncol. 2024;191:110064.","journal-title":"Radiother Oncol"},{"issue":"32","key":"11_CR113","doi-asserted-by":"publisher","first-page":"3795","DOI":"10.1200\/JCO.24.00081","volume":"42","author":"EB Ludmir","year":"2024","unstructured":"Ludmir EB, Sherry AD, Fellman BM, Liu S, Bathala T, Haymaker C, et al. Addition of metastasis-directed therapy to systemic therapy for oligometastatic pancreatic ductal adenocarcinoma (EXTEND): a multicenter, randomized phase II trial. J Clin Oncol. 2024;42(32):3795\u2013805.","journal-title":"J Clin Oncol"}],"container-title":["Cancer Treatment and Research","Immunotherapies in Solid Tumors"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-031-97242-3_11","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T23:04:44Z","timestamp":1778886284000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-031-97242-3_11"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"ISBN":["9783031972416","9783031972423"],"references-count":113,"URL":"https:\/\/doi.org\/10.1007\/978-3-031-97242-3_11","relation":{},"ISSN":["0927-3042","2509-8497"],"issn-type":[{"value":"0927-3042","type":"print"},{"value":"2509-8497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"23 August 2025","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}